CYduct Diagnostics (OTCMKTS:CYDX) Stock Rockets 455% in 6-Month: What’s The Buzz?

CYduct Diagnostics (OTCMKTS:CYDX) stock was in focus as the stock ended slightly lower on Thursday. The stock has soared 455% over the past 6-month.

Market Action

In the previous trading session, CYDX slid 0.90% to $1.11. A total of 1K shares traded for the session hands, well above its average volume of 137 shares. The stock opened at $1.55 and moved in a range of $1.1100 – 1.5500.

Key Trigger

CYduct Diagnostics, Inc. Announces Year-End Financial Results for Fiscal 2021

CYduct Diagnostics filed with OTC Markets its financial results for the fiscal years-ended June 30, 2021 and 2020. Commenting on the Company’s fiscal 2021 financial performance and key corporate milestones, Dominick Gatto, Chief Executive Officer stated, “Despite the challenges of the COVID-19 pandemic, we made significant progress in the fiscal year ended June 30, 2021, as we completed our capital restructuring and name change transactions and began to implement our vision of establishing CYduct Diagnostics as a leading company providing innovative solutions within the women’s healthcare marketplace.

We have taken several steps during the last fiscal year to accelerate our growth plans, such as enhancing our financial reporting structure, expanding our clinical strategies, making a strategic acquisition which we believe will be accretive, and solidifying our key strategic research agreement with Yale University.”

Key Quote:

Mr. Gatto continued, “Our expansion strategy is now beginning to take shape as we continue to facilitate plans to enhance our revenue potential and bottom-line performance. Our recent acquisition and the research project with Yale University should provide us with a forward-looking revenue platform to significantly exceed our historical revenues. We are focused on playing a key role in serving the women’s healthcare market, and therefore, we will continue to develop and invest in our intraductal breast health product lines.”